- Title
- A pathogenic role for tumor necrosis factor-related apoptosis-inducing ligand in chronic obstructive pulmonary disease
- Creator
- Haw, T. J.; Starkey, M. R.; Inman, M. D.; Wark, P. A.; Foster, P. S.; Knight, D. A.; Mattes, J.; Yagita, H.; Adock, I. M.; Horvat, J. C.; Hansbro, P. M.; Nair, P. M.; Pavlidis, S.; Liu, G.; Nguyen, D. H.; Hsu, A. C.; Hanish, I.; Kim, R. Y.; Collison, A. M.
- Relation
- Mucosal Immunology Vol. 9, p. 859-872
- Publisher Link
- http://dx.doi.org/10.1038/mi.2015.111
- Publisher
- Nature Publishing Group
- Resource Type
- journal article
- Date
- 2016
- Description
- Chronic obstructive pulmonary disease (COPD) is a life-threatening inflammatory respiratory disorder, often induced by cigarette smoke (CS) exposure. The development of effective therapies is impaired by a lack of understanding of the underlining mechanisms. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a cytokine with inflammatory and apoptotic properties. We interrogated a mouse model of CS-induced experimental COPD and human tissues to identify a novel role for TRAIL in COPD pathogenesis. CS exposure of wild-type mice increased TRAIL and its receptor messenger RNA (mRNA) expression and protein levels, as well as the number of TRAIL⁺CD11b⁺ monocytes in the lung. TRAIL and its receptor mRNA were also increased in human COPD. CS-exposed TRAIL-deficient mice had decreased pulmonary inflammation, pro-inflammatory mediators, emphysema-like alveolar enlargement, and improved lung function. TRAIL-deficient mice also developed spontaneous small airway changes with increased epithelial cell thickness and collagen deposition, independent of CS exposure. Importantly, therapeutic neutralization of TRAIL, after the establishment of early-stage experimental COPD, reduced pulmonary inflammation, emphysema-like alveolar enlargement, and small airway changes. These data provide further evidence for TRAIL being a pivotal inflammatory factor in respiratory diseases, and the first preclinical evidence to suggest that therapeutic agents that target TRAIL may be effective in COPD therapy.
- Subject
- chronic obstructive pulmonary disease (COPD); tumor necrosis; inflammatory respiratory disorders; cigarette smoke
- Identifier
- http://hdl.handle.net/1959.13/1310210
- Identifier
- uon:21994
- Identifier
- ISSN:1933-0219
- Language
- eng
- Full Text
- Reviewed
- Hits: 16776
- Visitors: 16924
- Downloads: 279
Collections
Goal 3: Good Health and Well-Being
| Thumbnail | File | Description | Size | Format | |||
|---|---|---|---|---|---|---|---|
| View Details Download | ATTACHMENT01 | Publisher version | 4 MB | Adobe Acrobat PDF | View Details Download |